Exparel Approved for Post-Surgery Pain

Provides relief up to 72 hours

MONDAY, Oct. 31 (HealthDay News) -- Exparel (bupivacaine liposome injectable suspension) has been approved by the U.S. Food and Drug Administration to treat post-surgical pain, maker Pacira Pharmaceuticals said Monday.

The product combines the long-acting anesthetic bupivacaine with Pacira's DepoFoam delivery technology. A single dose can provide relief for up to 72 hours and reduce the need for opioid painkillers, the drug maker said in a news release.

Exparel was evaluated in 21 clinical studies, including more than 1,300 participants. The most common side effects reported included nausea, constipation, and vomiting, Pacira said.

The company is based in Parsippany, N.J.

More information

To learn more about pain, visit Medline Plus.

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events